
EU’s CHMP Reaffirms Positive Opinion of Alzheimer Treatment Lecanemab
According to a recent announcement, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) reasserted stance on its recent positive opinion of lecanemab (Leqembi; Eisai), an antiamyloid therapy for patients with …